SCYNEXIS Inc
Save
–
Market cap
1.05x
Current P/E
2.26x
Forward P/E
About
Health care
Sector
Drug Manufacturers - Specialty & Generic
Industry
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
Similar securities
Based on sector and market capitalization
Report issue